Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. LipoScience's annualizedGross Profit for the quarter that ended in Sep. 2014 was €19.52 Mil.
LipoScience's average Total Assets over the quarter that ended in Sep. 2014 was €48.69 Mil. Therefore, LipoScience's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2014 was 40.10%.
LipoScience Gross-Profit-to-Asset % Historical Data
The historical data trend for LipoScience's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of LipoScience's Gross-Profit-to-Asset %
For the Diagnostics & Research subindustry, LipoScience's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LipoScience's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, LipoScience's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where LipoScience's Gross-Profit-to-Asset % falls into.
LipoScience Gross-Profit-to-Asset % Calculation
LipoScience's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2013 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Sep. 2014) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
LipoScience Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of LipoScience's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
LipoScience Inc was incorporated under the laws of North Carolina in June 1994 under the name LipoMed, Inc. and reincorporated under the laws of Delaware in June 2000. The Company is a clinical diagnostic company into field of personalized diagnostics based on nuclear magnetic resonance technology. The Company's first diagnostic test, the NMR LipoProfile test, is cleared by the U.S. Food and Drug Administration, and directly measures the number of low density lipoprotein, particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company's technology platform combines proprietary signal processing algorithms and NMR spectroscopic detection into a clinical analyzer to identify and quantify concentrations of lipoproteins and, potentially, small molecule metabolites. NMR detectors, or spectrometers, analyze a blood plasma or serum sample by subjecting it to a short pulse of radio frequency energy within a strong magnetic field. The Company currently markets NMR LipoProfile test through a direct sales force in 27 states. The Company competes against companies that offer other methods for measuring lipoproteins. Its competitors include Quest Diagnostics, Berkeley HeartLab, Inc., Atherotech, Inc. and SpectraCell Laboratories. The Company is subject to extensive and frequently changing federal, state and local laws and regulations governing various aspects of its business.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:LI0 has been successfully added to your 